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Abstract
Background: The underlying axiom in applying generic drugs is the equivalence of their active ingredient with 
the (usually more expensive) innovator product, an all-embracing statement with the insidious result that physicians 
assume that the generic products have been subjected to the same rigorous testing regimens as the brand-name 
products. The present paper presents novel experimental data on an investigator-blinded comparison between the 
innovator imipenem antibiotic, and a number of its generics. 
Methods: Particulate matter contamination of each group was visualized by means of a membrane filter method. 
Functional studies in an animal model–the dorsal skinfold chamber technique in mice-designed to simulate the state of 
microcirculatory dysfunction in intensive care patients was performed, in order to assess the influence of the particulate 
matter of each group on the functional capillary density of the striated skin muscle, after their intravenous injection. 
Results: The results showed massive particulate contamination of the generics, in a size range relevant for 
impacting the microcirculation. The particulate contamination contributed in some generic groups to a significant shut-
down of tissue perfusion. 
Conclusion: The presented data underscore the need to raise the regulatory barriers for the entry of generics 
to the market, well beyond the simplistic proof of “bioequivalence”, which in no measure deals with the essential 
questions of quality and patient safety. If generics are used, they should be tested by a filter technique and optical 
microscopy, to ensure the absence especially of small particulate contaminants and their purity.
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Introduction
Generic drugs are prevalent in current medical practice, and as a 
result of the prevailing economics of modern health care systems, they 
are being propagated as the medications of choice [1]. The usage of 
generic drugs is generally based upon the presumption that their active 
compounds are as efficacious as that of the innovator products, but 
cheaper and therefore desirable from an economic point of view [2-
4]. For that reason, many countries have established the commitment 
to generic drugs (by laws and directives), as a chance to reduce the 
exploding costs of their healthcare systems [4-7]. The US government 
passed  a  law  package,  the  US  Drug  Price  Competition  and  Patent 
Restoration  Act  (Public  Law  98-417,  “Hatch-Waxman  Act”),  that 
opened the market for a high level of generic drug sales [8,9]. One 
enactment of this act includes the drug price competition section, in 
which the approval process for generic drugs that is regulated by the US 
Federal Drug Administration (FDA) was altered [8,9]. Thus, the FDA 
was directed to assess the approval of a generic drug by pharmaceutical 
equivalence and bioequivalence studies, as well as abbreviated new 
drug applications (ANDAs), that generally do not require preclinical 
and clinical data to establish safety and effectiveness [9,10]. Due to that 
the FDA applies the “plus-or-minus-twenty-percent test”, by which 
the amount of the active compound in the blood over a period of time 
has to be within plus-or-minus 20%, in comparison to the innovator 
drug [9]. The FDA states on its website in answer to the question “Are 
generic drugs as effective as brand-name drugs?”: “Yes, a generic drug 
is the same as a brand-name drug in dosage, safety, strength, quality, 
the way it works, the way it is taken, and the way it should be used” 
[2]. A similar practice concerning approval of generic drugs has been 
adopted in the states of the European Union [7,11].
Despite the political promotion of the use of generic drugs and the 
establishment of a legal framework, numerous data exist which describe 
complications related to this medication class [12-15]. Additionally 
to differences between the bioequivalence of innovator products and 
generics, major concerns associated with abrupt discontinuation of the 
former, and a switch to generics had been reported [15-17]. Quality 
issues have also been raised in the USA by the so-called “four-dollar” 
generics, making low-cost medication widely accessible through major 
pharmacy chains [18]. These developments have contributed to doubts 
about the efficacy and quality of generics, especially in the view of older 
physicians and pharmacists [19].
Following public consultations on proposals to implement generic 
substitution in primary care, the UK Department of Health recently 
decided against introducing any such law [20]. One of the key issues 
in the decision not to pursue a legal requirement was “the perception 
strongly held by consultation respondents that generic substitution 
posed a threat to patient safety” [20]. Although not stated, it is likely 
that these safety concerns were expressed by the medical profession, 
rather than by health economists. 
Previously published data by our group as well as novel data in this 
article, contradict a global uncritical approval of generic drugs. Whilst 
no view will be expressed on risks associated with oral medication with 
generics, we will focus exclusively on the intravenous administration 
route in severely ill patients [21]. Former work from our laboratory Volume 2 • Issue 1 • 1000109 Pharmaceut Reg Affairs
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involved a detailed study of generics of the antibiotic cefotaxime, in 
which the innovator product, Claforan®, was compared with some of 
its generics [21]. This in vivo study was designed to test the possible 
functional  significance  of  particulate  contaminants,  and  aimed  at 
simulating  the  state  of  the  microcirculation  in  a  typical  patient  in 
the  intensive  care  unit  (ICU),  that  is,  generally  with  some  degree 
of  multiple  organ  dysfunction  syndrome  (MODS),  in  the  form  of 
microcirculatory dysfunction [22-25]. This was simulated using the 
rodent  “dorsal  skinfold  chamber  technique”,  which  permits  direct 
observation of the microcirculation in an awake animal for a period 
of  up  to  21  days,  with  quantification  of  important  physiological 
parameters of the microcirculation [26]. Microcirculatory dysfunction 
was induced by ischemia and reperfusion (I/R) injury, and the state 
monitored  by  the  functional  capillary  density  (FCD),  that  is  the 
percentage of the capillary system in the observed microcirculation 
being  actively  perfused,  as  quantitatively  determined  from  images 
taken randomly from video microscopy. The study using cefotaxime 
generics  demonstrated  in  a  membrane  filter  technique  that  many 
generics were contaminated by foreign particulate matter, and that 
intravenous injection of these particles in the rodent model caused 
further shut-down of the compromised microcirculation [21]. Detailed 
histological analysis of the skin window tissue revealed particulates in 
the lumen of capillary branches.
In the present study, a different antibiotic, imipenem in the form of 
the innovator product, and a number of its worldwide generics, were 
investigated both by the membrane filter method to visualize particulate 
contaminants, and the dorsal skinfold chamber technique, but using in 
the latter a mouse model instead of the hamster. The data demonstrate 
that this imipenem investigation yields similar results to the cefotaxime 
data, with respect to the deleterious effect on tissue perfusion. However, 
in contrast to the earlier study, in which the particulates were detected 
in the tissue with impaired perfusion, the present study showed marked 
microcirculatory shutdown, without particulate matter being found in 
the affected region. This would suggest functional disturbances beyond 
the simple mechanisms of mechanical blockage of the microcirculation, 
and will require more detailed investigation.
Materials and Methods
Source of innovator product and generics 
The imipenem innovator product, “Tienam®” was kindly provided 
by Merck, Sharp and Dohme (MSD, USA). The generics Prepenem®, 
Tilam®, Yungjin® and Zilonem® were obtained from Korea, Taiwan, 
Thailand and India, respectively. All samples were in powder form in 
sterile vials as for clinical use. Each vial contained 1 g of sterile powder 
of each of the above-mentioned antibiotics.
In vivo study 
Animals:  The  animal  experiments  were  performed  after  being 
approved by the Committee on the Use of Live Animals in Teaching 
and Research, Rhineland-Palatinate, Germany. A total of 24 female 
CD-1 mice (6- to 8-week old, 20–25 g body weight, Charles River 
Laboratories,  Sulzfeld,  Germany)  were  randomly  divided  into  five 
experimental and one control group (n=9). The animals were housed 
one  per  cage,  kept  with  water  ad  libitum,  an  artificial  light–dark 
regime, and fed with regular mouse pellets (Laboratory Rodent Chow, 
Altromin, Germany), at the Laboratory Animal Unit of the Institute of 
Pathology, Johannes Gutenberg University Mainz, Germany. 
Particulate  separation  for  in  vivo  application:  The  particulate 
matter separation for the in vivo application was performed according 
to the described method of Lehr et al. [21]. In brief, 100 ml of sterile 
saline  (0.9%;  Braun,  Melsungen,  Germany)  were  injected  into  the 
original vials, in order to dissolve the powder within each vial. A filter 
with a pore size of 0.2 µm (Supor® 200 PES Membrane Disc Filter, Pall 
Life Science, USA), was used in order to filter the solution. The residuals 
on the filter membranes were then resuspended in 10 ml of the above-
mentioned saline. Subsequently, a centrifugation process of 15 min at 
4500 rpm was performed. The acquired pellets were resuspended in 
100 µl of normal saline, and injected intravenously as a bolus into the 
animals via the in-dwelling catheter.
Skinfold  chamber  animal  model,  catheter  implantation  and 
experimental set up: For intravital fluorescence microscopy, the dorsal 
skinfold chamber preparation as well as the application of an indwelling 
catheter in the jugular vein in the CD-1 mouse was performed according 
to  the  previously  described  method  [21,22,26].  The  application  of 
this  model  permits  the  intravital  microscopic  visualization  and 
quantification of the nutritional capillary perfusion in finely striated 
skin muscle [21,22,26]. An image of the skinfold chamber set up is 
given in figure 1. The study was initiated after a time period of up to 3 
days, in which inflammation related to operation was excluded. In each 
mouse, 10 identical microvascular regions of interest per chamber, 
each containing several parallel capillaries in the foreground, and one 
characteristic draining venule for orientation purposes were studied, 
visualized and recorded using intravital fluorescence microscopy. These 
same regions of interest were evaluated at baseline, after four hours of 
ischemia, and after two hours of reperfusion (post-ischemic value), and 
10 minutes after injection of the antibiotic particulate solutions. 
Immediately  before  the  microscopical  studies,  fluorescein 
isothiocyanate-conjugated  macromolecular  dextran  (FITC–dextran, 
Mr  150,000,  5  mg  in  100  μl  of  saline;  Sigma,  St.  Louis,  MO)  was 
injected intravenously, in order to visualize the plasma column. The 
pressure induced an ischemia of four hours, and was performed by 
gently pressing the muscle against the coverslip with a silicone pad 
and an adjustable screw, just sufficient to empty the blood vessels. For 
each experimental group, the particulate matter from the antibiotic 
solutions in 100 µl of normal saline was injected intravenously via the 
implanted catheter. The animals of the control group received only 
100 µl of normal saline solution. All experiments were performed in a 
double-blinded fashion.
Image  analysis:  Image  analysis  was  performed  according  to  a 
previously described method [21,22,26]. The region of interest within 
Figure  1:  Macroscopic  and  microscopic  images  of  the  skinfold  chamber 
model. (A) shows a macroscopic overview of the area of a skinfold chamber 
after ischemia and reperfusion. Note the major vessels (arrows) within the 
subcutaneous tissue that pass into the capillaries (arrow heads), which are 
subsequently microscopically assessed (25X magnification). Volume 2 • Issue 1 • 1000109 Pharmaceut Reg Affairs
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the striated muscle microcirculation was visualized and recorded at 
each study time point at 100X magnification by using a fluorescent 
microscope, with a 100 W mercury lamp (ECLIPSE 80i microscope, 
Nikon, Tokyo, Japan), equipped with standard blue/green/red filters, in 
addition to a bright field source (Figure 2). Functional capillary density 
(FCD) was quantified using the image analysis system, NIS-Elements 
BR 3.0 (Nikon, Tokyo, Japan). Only capillaries that were perfused with 
red blood cells were used for assessment of the parameter FCD (Figure 
2) [21,22,26]. The applied technique of quantifying functional capillary 
density enables reproducible results to be acquired, and is associated 
with a low interobserver variability [21].
Tissue preparation and histology: At the end of each study, the 
animals were euthanized by an overdose of ketamine and xylazine. 
For the purpose of characterization of the effects of particulate matter 
on the microcirculation, the tissue and organs, i.e. the tissue of the 
skinfold chamber, as well as the heart, lung, liver, kidney and spleen 
of the animals, were explanted and fixed in 4% buffered formalin for 
24 h for further histological preparation. After dehydration in a series 
of graded alcohols, followed by xylene treatment, paraffin embedding 
was performed. For all tissue samples, serial sections at an interval of 50 
μm were made. From each interval, two consecutive 3-4 μm thick slices 
were made and stained with Mayer’s haematoxylin and eosin (H&E) 
and Giemsa for further histopathological examination (Figure 1). These 
sections were examined by two independent investigators for any effect 
of particle contamination. The investigations were conducted using a 
Nikon ECLIPSE 80i microscope (Nikon, Japan). Microphotographs 
were taken using a Nikon DS-Fi1 digital camera and a digital sight 
control unit (Nikon, Japan).
Statistical analysis:  Quantitative  data  are  presented  as  mean  ± 
standard deviation, and an analysis of variance (ANOVA) was carried 
out. Differences were considered significant if P-values were less than 
0.05 (*P<0.05), and highly significant if P-values were less than 0.01 or 
0.001 (**P<0.01/***P<0.001). IBM® SPSS® Statistics 18 (SPSS Inc., an 
IBM Company, USA) was used for all calculations. GraphPad Prism 
5.0d software (GraphPad Software Inc., La Jolla, USA) was used for 
plotting graphs.
Particulate separation for particle size characterization 
The particulate matter separation for particle size characterization 
was  performed  according  to  the  described  method  of  Kirkpatrick 
and  Rangoonwala  [27].  In  brief,  demineralized  particle-free  water 
(DPFW) was prepared using a Super-Q Plus Ultra Purification System 
(Millipore,  USA).  Subsequently,  the  purity  of  the  demineralised 
water was verified with the aid of a membrane filter (MF-Millipore™ 
Membrane Filters, 25 mm filter diameter, 0.8 µm pore size Millipore, 
USA). The filters were evaluated and documented using an Olympus 
SZX12 stereomicroscope (Olympus, Japan). In a next step, a filtration 
apparatus was used for membrane filtration of the antibiotic vials based 
on a filtration funnel (Advantec, Ireland), and a vacuum tube connected 
to  an  evacuation  system,  in  combination  with  cellulose  membrane 
filters (MF-Millipore™ Membrane Filters, 25 mm filter diameter, 0.8 
µm pore size, Millipore, USA). Furthermore, this system consisted of a 
vacuum pump (membrane pump with remaining pressure of 30 mbar), 
a collecting vessel and a tubing system.
For visualization of particulate matter contamination, the contents 
of one 500 mg vial of the antibiotics were dissolved in 100 ml DPFW. 
The dissolved solution of 3 vials was filtered under less than 500 mbar 
vacuum  through  the  membrane  filter.  The  whole  procedure  was 
performed under clean room conditions with minimized particulate 
burden (laminar flow bench). Following this, the membrane filters were 
fixed in sealable particle-free containers (Petri dishes, PALL, Germany). 
Filters  were  viewed  under  an  Olympus  SZX  12  stereomicroscope 
(Olympus,  Japan),  and  documented  by  Hitachi  HV-C  20M  video 
camera (Hitachi, Japan) that was connected to a combined computer 
system. Using the software Analysis SIS, Version 3.1 (Olympus, Toyko, 
Japan), the microscope video prints could be viewed on the monitor 
and the data stored on the hard disk. For each product 3 filters were 
prepared.
Results
Drug-induced impairment of the microcirculation
Intravital microscopy in the mouse skin window technique was 
used to test the effects of injecting the various drug groups into a 
microcirculation  made  dysfunctional,  using  ischaemia/reperfusion 
(I/R) injury to simulate the state of organ perfusion of intensive care 
patients. The administered imipenem groups were tested in a blinded 
fashion, i.e. they were known to the experimental team only as a code, 
which was revealed after data collection. Figure 3 shows that prior to 
injection of the drug, the functional capillary density (FCD) of the 
various generic or innovator product groups (B to F) after I/R injury 
showed no statistically significant differences from the control group 
A
B
C
Figure 2: Representative images of capillaries within the striated panniculus 
carnosus muscle in a skinfold chamber to demonstrate the FCD after treatment 
by Tilam®. Contrast enhancement was achieved by intravenous injection of 
FITC-labelled macromolecular dextran (FITC–dextran). The blocked capillaries 
are manually marked with green color. (A) shows the state of vascularization 
before ischemia and reperfusion, (“baseline”). (B) shows the state of perfusion 
of the capillaries after ischemia and reperfusion while (C) shows the same 
capillaries after particle injection (200x magnification, scale bars=10 μm).Volume 2 • Issue 1 • 1000109 Pharmaceut Reg Affairs
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(A). All were approximately 85% of the baseline value (100%), the latter 
representing the measured FCD prior to microcirculatory damage.
Measurement of FCD following drug injection revealed marked 
differences between the various drug groups and the control. Thus, 
figure 3B indicates that two groups, C and F, did not differ from the 
control, in which saline only was injected. By contrast, the groups 
D and E (P<0.01) and especially group B (P<0.001) demonstrated a 
marked, statistically significant reduction in FCD, compared to the 
control. On breaking the code, it became evident that the drug groups 
non-significantly different from the control were the innovator product 
(F, Tienam®) and its generic Prepenem® (C). The generics Tilam®, 
Yungjin® and Zilonem® (B, D and E resp.) were responsible for marked 
deleterious effects on microcirculatory perfusion, with FCD levels of 
66.93 ± 5.25%, 76.88 ± 6.37% and 79.56 ± 8.83% of the control (A), 
respectively.
With the exception of the spleen, almost no particles were found 
within the microcirculatory bed of the skinfold chamber region. No 
particulate matter was observed in the heart, lungs, liver and kidneys of 
each animal in the study (data not shown).
Physical characterization of the imipenem samples
Using  the  separation  technique  described  in  the  materials  and 
methods  section,  it  was  demonstrated  that  the  generic  drugs  used 
in this study were contaminated by a heterogeneous population of 
particulates, ranging from elongated fibres to smaller, dense and more 
spherical particles. It was not the aim of the study to perform detailed 
quantitative analysis on these filters, but principally to determine if 
there was an easily visible contamination of the generic drugs with 
particulates,  and  to  compare  this  with  the  innovator  product.  The 
discoloration  of  some  of  the  filters  from  the  generics  supports  the 
presence of additional soluble contaminants, which are most probably 
leached out from the particulates. Further investigations are required to 
identify their molecular structure, but they could be readily identified 
by chromatographic or mass spectroscopic techniques.
Large numbers of particles of a size relevant for the microcirculation 
were indeed seen in those generics, which aggravated the compromised 
microcirculation in the animal model. Representative images of the 
drug samples after the membrane filter method are given in figure 4. 
In group E (Zilonem®, Figure 4E), numerous particles were between 1 
and 3 µm, as well as in the filters of group B (Tilam®, Figure 4B), which 
gave the greatest impairment of capillary perfusion. Interestingly, the 
generic C (Prepenem®, Figure 4C) which had predominantly elongated 
fibre-like particles, which ranged between 5-20 µm that is of a size 
incapable  of  entering  the  capillaries,  did  not  show  any  statistically 
significant decrease in the functional capillary density (FCD) in the 
animal study. Thus, there appears to be a good correlation between 
the size range of particulate contamination and the effects observed 
in the dorsal skinfold chamber. This does not mean, of course, that 
such fiber contamination is innocuous, as it appears that this larger 
size range of particle is shunted into other circulatory beds. In group 
D (Yungjin®, Figure 4D), most particles were found between 1 and 5 
µm. In group F (Tienam® Figure 4F), also round-shaped particles were 
found, which ranged between 1 and 3 µm. No particles were found 
within the group A, the control group without antibiotic (Figure 4A). 
In the generic groups, i.e. groups B, C, D and E, the particle numbers 
were too numerous to count. 
Discussion
The  interest  of  this  work  for  intensive  care  medicine  derives 
from  the  fact  that  a  typical  patient  on  Intensive  Care  Unit  (ICU) 
receives large volumes of fluid, as well as medication intravenously. 
Our  working  hypothesis  was  that  particulate  contaminants  in  the 
administered solutions could represent a health hazard for the patient 
by  causing  mechanical  blockage,  and/or  endothelial  activation  in 
the microcirculation. This was the motivation for the development 
of  a  relevant  functional  model  in  an  experimental  animal.  Our 
model  was  designed  to  simulate  as  closely  as  possible  the  state  of 
the  microcirculation  in  a  typical  intensive  care  patient.  Numerous 
studies have shown that ICU patients with multiple organ dysfunction 
syndromes  (MODS)  have  varying  degrees  of  microcirculatory 
dysfunction,  irrespective  of  whether  they  are  post-traumatic,  post-
infection etc. [24].
Figure 3: The graphical illustration of the measured Functional Capillary Density (FCD) within the muscle tissue of the skinfold chamber after (A) ischemia and 
reperfusion, and after (B) antibiotic particle injection. Values are given as mean ± standard deviation of the mean, and statistical significance was tested for each drug 
group against the control (**P< 0.01; ***P< 0.001).Volume 2 • Issue 1 • 1000109 Pharmaceut Reg Affairs
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Using the membrane filter method, the results of this study reveal 
that many generics contain foreign particulate material, and this raises 
the pertinent question how such a state is possible in a regulatory 
environment. To identify the chemical composition of contaminating 
particles, additional studies are currently being performed on selected 
filters using scanning electron microscopy (SEM) and energy-dispersive 
analysis of X-rays (EDAX) as shown by Walpot et al. [28].
It  is  instructive  to  compare  the  demands  made  on  companies 
bringing an innovative drug on to the market and those making its 
generic.  The  former  must  perform  every  step  according  to  Good 
Manufacturing Practice (GMP) standards, i.e. there are safety checks at 
all involved stages. For approval, a generic must demonstrate so-called 
bioequivalence, which in the EMEA (European Medicines Agency) 
guideline of January 2010 is defined as follows: “Two medicinal products 
containing the same active substance are considered bioequivalent, if 
they are pharmaceutically equivalent or pharmaceutical alternatives 
and their bioavailabilities (rate and extent), after administration in the 
Figure 4: Representative images of the filters used for the filtration method to detect particulate matter contamination. Note the numerous particulates (<5 µm) in the 
generics Tilam® (B), Yungjin® (D) and Zilonem® (E), while the generic Prepenem® (C) showed mostly elongated, fibre-like particles.  The filters of the saline control 
group is free (A) and the Tienam® group (F), almost free of particulate contamination. Volume 2 • Issue 1 • 1000109 Pharmaceut Reg Affairs
ISSN: 2167-7689 PROA, an open access journal
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same molar dose lie within acceptable predefined limits. These limits 
are set to ensure comparable in vivo performance, i.e. similarity in 
terms of safety and efficacy” [29]. Whilst the present report concerns 
itself experimentally with particulate contamination, there is further 
evidence from the literature that generics also suffer from fluctuating 
dosage. Thus, for example, in a single-dose pharmacokinetic assessment 
(in healthy volunteers) of two amoxicillin generics in Italy, one was 
found to be not bioequivalent with the innovator product [30]. Even 
changing the salt form, for example, of the calcium channel blocker, 
amlodipine, has been shown to alter drug stability and the formation 
of impurities [31]. On plotting the mean plasma concentration against 
the time after dosage, the AUC (area under the concentration-time 
curve) can be calculated, and this, together with the maximum plasma 
concentration Cmax, are the usual pharmacokinetic variables used to 
assess bioavailability. Although the tolerance range for bioequivalence 
is usually taken as between 80 and 125%, studies by the FDA in the 
1990’s  comparing  innovator  products  and  their  generics  indicated 
that the observed differences were less than 5% [32,33]. Despite the 
fact that such historical data are very useful to study trends, they have 
no  predictive  value  for  any  new  generic  appearing  on  the  market. 
Moreover,  there  are  patient  groups  such  as  epileptics  for  whom 
the  therapeutic  window  for  the  drugs  of  choice  is  narrow,  so  that 
bioequivalence can scarcely be defined so broadly [34]. The tolerance, 
with respect to bioavailability, is also critical in severely ill patients 
requiring  antimicrobial  treatment,  and  the  risks  associated  with 
underdosage of antibiotics are well described, such as the induction of 
bacterial resistance [35].
In vitro studies are also being used to compare the antimicrobial 
activity of an innovator product and its generics. Thus, Diaz et al. [36] 
made comparisons of vancomycin preparations and found similarity, 
for example, with respect to minimal inhibitory concentrations (MICs), 
minimal  bactericidal  concentrations  (MBCs)  and  resistant  mutants 
etc., concluding that this demonstrated pharmaceutical equivalence. 
By  contrast,  Vesga  et  al.  [37]  performed  similar  comparisons  on 
vancomycin innovator product and its generics, but looked additionally 
at equivalence of efficacy in vivo. This latter group also demonstrated 
no  differences  in  antibacterial  effect  in  vitro,  but  reported  that  all 
generics which were tested failed to kill Staphylococcus aureus in a 
neutropenic mouse thigh infection model. Their conclusion was that 
“pharmaceutical equivalence does not imply therapeutic equivalence 
for  vancomycin”  [37].  Moreover,  a  recent  publication  from  this 
group demonstrated in the same experimental model that a generic 
vancomycin favoured the development of resistance in a subpopulation 
of Staphylococcus aureus under the therapy [38]. It is evident that the 
only relevant equivalence for clinical practice is the therapeutic one.
Pharmacoeconomics is a field of endeavour which is gaining in 
importance, as health care depends on budget availability, the latter 
ultimately being determined by governmental policy at both national 
and local level. Cost minimization is an all-pervading principle, which 
has led to the almost axiomatic statement that generic drugs can and 
should be prescribed, as they are equivalent to brand-name medication 
except for their lower price.
ICU physicians are very aware of the fact that microbial infections 
need to be treated effectively to reduce mortality and keep costs to a 
minimum. Pittoni and Scatto [39] showed that in severely ill patients 
the major cost components come from mechanical ventilation and 
sepsis management, while Dasta et al. [40] calculated on the basis of 
data from 253 US hospitals that mean incremental costs of mechanical 
ventilation  amount  to  >  $US  1.500,00  per  day.  In  a  Norwegian 
University  hospital  setting,  Flaatten  and  Kvale  [41]  determined 
average costs of an ICU day at € 2601,00. More recently, for the South 
American continent, Sogayar et al. [42] evaluated the costs of ICU 
treatment of septic patients in Brazil, concluding that the median daily 
ICU cost per patient was $US 934,00, but that this was even higher, 
namely  $US  1.094,00,  for  non-survivors.  In  a  Canadian  study  on 
published and institutional data, Muscedere et al. [43] described an 
ICU bed as costing CAN dollars 2.396,00 per day. Of relevance for the 
present discussion is their calculation that each episode of ventilator-
associated pneumonia (VAP) extended the ICU stay on average by 4.3 
days, which extrapolated to other countries could amount to additional 
costs, varying between $US 4.000,00 and $US 15.000,00. The medical 
and economic problems of VAP are also highlighted by Eagye et al. 
[44], who studied the economic impact of respiratory superinfection 
in patients being treated for VAP. This detailed study in 74 patients 
discharged between 2004 and 2005 showed that mean costs for the 
ICU stay differed by approximately $US 67.000,00, if the patients being 
treated for VAP developed a superinfection (mainly P. aeruginosa, S. 
aureus, Klebsiella spp.). This extract from the literature makes it very 
clear that the economic burden on the health system is enormous, 
if ICU patients are ineffectively treated for bacterial infections. It is 
self-evident that this will be the case if patients are administered sub-
standard medications, as seen by some generics studied in the present 
paper.
The  data  from  our  previous  study  on  generic  cefotaxims  by 
Lehr et al. [21], and the data generated in this paper with imipenem 
generics clearly contradict the view that there is equivalence in quality 
between the originator products and their generics. There are practical 
conclusions to be drawn from the present study. It is evident that 
in vivo testing with a sophisticated model as presented here is not 
feasible for the numerous generic preparations used in contemporary 
medicine.  However,  for  intensive  care  medicine,  in  which  most 
medication is given intravenously, there is a strong case to be made for 
using a membrane filter technique and optical microscopy to check the 
quality of drugs to be administered to ICU patients. Indeed, this is a 
recommendation that is to be found in all three major pharmacopoeial 
texts for testing sub-visible particles (European Pharmacopoeia 2005, 
Japanese  Pharmacopoeia  2006,  United  States  Pharmacopeia  2007). 
Based on our studies, we have to assume that these recommendations 
are not being followed. Having a sub-visible particle testing facility in a 
hospital pharmacy with the possibility of serving a series of hospitals in 
a region would be an economically viable model. Our data indicate that 
the presence of a large number of small particle contaminants correlates 
with  functional  disturbance  in  the  microcirculation.  Thus,  on  this 
basis, such drugs could be removed from the hospital’s purchasing list. 
Finally, it is an indictment of contemporary, profit-driven medicine 
that the end-user appears compelled, in the interests of the patient, 
to set up quality control monitoring in lieu of companies, which are 
legally and morally obliged to perform such studies, but obviously do 
not.
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